Interstitial Lung Diseases in Developing Countries
References
- ATS/ERS. American Thoracic Society/European Respiratory Society International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002; 165(2): 277–304. DOI: 10.1164/ajrccm.165.2.ats01
- Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6): 733–748. DOI: 10.1164/rccm.201308-1483ST
- Valeyre D, Duchemann B, Nunes H, et al. Interstitial lung diseases. ERS Monograph. 2014; chapter 6, 65: 79–87.
- American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2): 646–664. DOI: 10.1164/ajrccm.161.2.ats3-00
- Bouros D. Current classification of idiopathic interstitial pneumonias. Monaldi Arch Chest Dis. 2000; 55(6): 450–454.
- Verleden GM, du Bois RM, Bouros D, et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J. 2001; 18(Suppl 32): 17s–29s.
- Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994; 150(4): 967–972. DOI: 10.1164/ajrccm.150.4.7921471
- Schweisfurth H. Report by the scientific working group for therapy of lung diseases: German fibrosis register with initial results. Pneumologie. 1996; 50(12): 899–901.
- Schweisfurth H, Kieslich C, Satake N, et al. How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases (“Fibrosis registry”) of the WATL. Pneumologie. 2003; 57(7): 373–382. DOI: 10.1055/s-2003-40557
- Thomeer M, Demedts M, Vandeurzen K and VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001; 56(3): 163–172. DOI: 10.1179/acb.2001.026
- Roelandt M, Demedts M, Callebaut W, et al. Epidemiology of interstitial lung disease (ILD) in flanders: Registration by pneumologists in 1992–1994. Working group on ILD, VRGT. Acta Clin Belg. 1995; 50(5): 260–268. DOI: 10.1080/17843286.1995.11718459
- Agostini C, Albera C, Bariffi F, et al. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis. 2001; 56(4): 364–368.
- Tinelli C, De Silvestri A, Richeldi L, et al. The Italian register for diffuse infiltrative lung disorders (RIPID): A four-year report. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22(Suppl 1): S4–S8.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–171. DOI: 10.1016/S0140-6736(14)61682-2
- ERS.
Interstitial lung diseases , In: ERS European Lung White-book. Chapter 22. ERS; 2015.http://www.erswhitebook.org/chapters/interstitial-lung-diseases/ . Access date: September 15, 2016. - Kreuter M, Herth FJF, Wacker M, et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: Rationale, aims, and design of a nationwide prospective registry—The EXCITING-ILD Registry. Biomed Res Int. 2015; Epub 2015 Nov 10. DOI: 10.1155/2015/123876
- Kreuter M, Herth FJF, Wacker M, et al. Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases). Eur Resp J. 2016; 48(Suppl 60):
PA3905 . DOI: 10.1183/13993003.congress-2016.PA3905 - Hyldgaard C. A cohort study of Danish patients with interstitial lung diseases: Burden, severity, treatment and survival. Dan Med J. 2015; 62(4): B5069.
- Xaubet A, Ancochea J, Morell F, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis. 2004; 21(1): 64–70.
- Lopez-Campos JL, Rodríguez-Becerra E and Neumosur Task Group, Registry of Interstitial Lung Diseases. Incidence of interstitial lung diseases in the south of Spain 1998–2000: The RENIA study. Eur J Epidemiol. 2004; 19(2): 155–161. DOI: 10.1023/B:EJEP.0000017660.18541.83
- Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009; 103(8): 1122–1129. DOI: 10.1016/j.rmed.2009.03.001
- Thomeer MJ, Costabel U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J. 2001; 18(Suppl 32): 114s–118s.
- Musellim B, Okumus G, Uzaslan E, et al. Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J. 2014; 8(1): 55–62. DOI: 10.1111/crj.12035
- Jindal SK and Gupta D. Incidence and recognition of interstitial pulmonary fibrosis in developing countries. Curr Opin Pulm Med. 1997; 3(5): 378–383. DOI: 10.1097/00063198-199709000-00011
- Collins B, Singh S, Joshi J, et al. ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD). Eur Resp J. 2016; 48(Suppl 60):
PA812 . DOI: 10.1183/13993003.congress-2016.PA812 - Alhamad EH. Interstitial lung diseases in Saudi Arabia: A single-center study. Ann Thorac Med. 2013; 8(1): 33–37. DOI: 10.4103/1817-1737.105717
- Martínez-Briceño D, García-Sancho C, Fernández-Plata R, et al. Tendencia de la mortalidad por enfermedades intersticiales en México, período 2000–2010. Neumol Cir Torax. 2014; 73(3): 179–184.
- ERS.
Occupational lung diseases . In: ERS European Lung White-book. Chapter 24. ERS; 2015.http://www.erswhitebook.org/chapters/occupational-lung-diseases/ . Access date: September 15, 2016. - The World Health Organization. Asbestos: Elimination of Asbestos-related Diseases. Fact sheet Nº343; 2010. Available at:
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/Mesothelioma/incidence/#source6 . Access date: March 7, 2016. - Prazakova S, Thomas PS, Sandrini A, et al. Asbestos and the lung in the 21st century: An update. Clin Respir J. 2014; 8: 1–10. DOI: 10.1111/crj.12028
- Baas P and Burgers S. SIA: Asbestos stop in Asia. Respirology. 2015; 20(4): 521. DOI: 10.1111/resp.12533
- Subramanian V and Madhavan N. Asbestos problem in India. Lung Cancer. 2005; 49(Suppl 1): S9–S12. DOI: 10.1016/j.lungcan.2005.03.003
- Baron PA. Measurement of airborne fibers: A review. Ind Health. 2001; 39(2): 39–50. DOI: 10.2486/indhealth.39.39
- Warheit DB, Reed KL and Webb TR. Man-made respirable-sized organic fibers: What do we know about their toxicological profiles? Ind Health. 2001; 39(2): 119–125. DOI: 10.2486/indhealth.39.119
- Roggli VL, Gibbs AR, Attanoos R, et al. Pathology of asbestosis—An update of the diagnosis criteria: Report of the asbestosis committee of the college of American pathologists and pulmonary pathology society. Arch Pathol Lab Med. 2010; 134(3): 462–480.
- American Thoracic Society. A diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004; 170(6): 691–715. DOI: 10.1164/rccm.200310-1436ST
- Donovan EP, Donovan BL, McKinley MA, et al. Evaluation of take home (para-occupational) exposure to asbestos and disease: A review of the literature. Crit Rev Toxicol. 2012; 42(9): 703–731. DOI: 10.3109/10408444.2012.709821
- Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: A case-control study. Br J Cancer. 2009; 100(7): 1175–1183. DOI: 10.1038/sj.bjc.6604879
- Ferrante D, Bertolotti M, Todesco A, et al. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect. 2007; 115(10): 1401–1405. DOI: 10.1289/ehp.10195
- Pérez-Alonso A, Córdoba-Doña JA, Millares-Lorenzo JL, et al. Outbreak of silicosis in Spanish quartz conglomerate workers. Int J Occup Environ Health. 2014; 20(1): 26–32. DOI: 10.1179/2049396713Y.0000000049
- Grewal KS, Arora VK and Gupta SP.
Industrial lung diseases . Progress in Clinical Medicine in India. 3rd series. Ahuja MMS (ed.). 1979; 420–438. New Delhi: Arnold Heinemann. - Leung CC, Yu IT and Chen W. Silicosis. Lancet. 2012; 379(9830): 2008–2018. DOI: 10.1016/S0140-6736(12)60235-9
- Carneiro APS, Barreto SM, Siqueira AL, et al. Continued exposure to silica after diagnosis of silicosis in Brazilian gold miners. Am J Ind Med. 2006; 49: 811–818. DOI: 10.1002/ajim.20379
- Nelson G, Girdler-Brown B, Ndlovu N, et al. Three decades of silicosis: Disease trends at autopsy in South African gold miners. Environ Health Perspect. 2010; 118: 421–426. DOI: 10.1289/ehp.0900918
- Akgun M, Araz O, Akkurt I, et al. An epidemic of silicosis among former denim sandblasters. Eur Respir J. 2008; 32: 1295–1303. DOI: 10.1183/09031936.00093507
- Kauppinen T, Toikkanen J, Pedersen D, et al. Occupational exposure to carcinogens in the European Union. Occup Environ Med. 2000; 57: 10–18. DOI: 10.1136/oem.57.1.10
- The World Health Organization. Silicosis. Fact sheet Nº238; 2000. Available at:
http://web.archive.org/web/20070510005843/ ,http://www.who.int/mediacentre/factsheets/fs238/en/ . Access date: March 7, 2016. - Linch KD, Miller WE, Althouse RB, et al. Surveillance of respirable crystalline silica dust using OSHA compliance data (1979–1995). Am J Ind Med. 1998; 34: 547–558. DOI: 10.1002/(SICI)1097-0274(199812)34:6<;547::AID-AJIM2>3.0.CO;2-B
- Rosenman KD, Reilly MJ and Henneberger PK. Estimating the total number of newly-recognized silicosis cases in the United States. Am J Ind Med. 2003; 44: 141–147. DOI: 10.1002/ajim.10243
- Parikh JR. Byssinosis in developing countries. Br J Ind Med. 1992; 49(4): 217–219. DOI: 10.1136/oem.49.4.217
- Parikh JR, Bhagia LJ, Majumdar PK, et al. Prevalence of byssinosis in textile mills at Ahmedabad, India. Br J Ind Med. 1989; 46(11): 787–790. DOI: 10.1136/oem.46.11.787
- Gupta S and Gupta BK. A study of byssinosis and associated respiratory disorders in cotton mill workers. Indian J Chest Dis Allied Sci. 1988; 28(4): 183–188.
- Barjatiya MK, Mathur RN and Swaroop A. Byssinosis in cotton textile workers of Kishangarh. Indian J Chest Dis Allied Sci. 1990; 32(4): 215–223.
- White NW. Byssinosis in South Africa. A survey of 2411 textile workers. S Afr Med J. 1989; 75(9): 435–442.
- Takam J and Nemery B. Byssinosis in a textile factory in Cameroon: a preliminary study. Br J Ind Med. 1988; 45(12): 803–809. DOI: 10.1136/oem.45.12.803
- Woldeyohannes M, Bergevin Y, Mgeni AY, et al. Respiratory problems among cotton textile mill workers in Ethiopia. Br J Ind Med. 1991; 48: 110–115. DOI: 10.1136/oem.48.2.110
- Awad el Karim MA, Osman Y and el Haimi YA. Byssinosis: environmental and respiratory symptoms among textile workers in Sudan. Int Arch Occup Environ Health. 1986; 57(2): 101–108. DOI: 10.1007/BF00381377
- Awad el Karim MA and Onsa SH. Prevalence of byssinosis and respiratory symptoms among spinners in Sudanese cotton mills. Am J Ind Med. 1987; 12(3): 281–289. DOI: 10.1002/ajim.4700120305
- Noweir MH, Noweir KH, Osman HA, et al. An environmental and medical study of byssinosis and other respiratory conditions in the cotton textile industry in Egypt. Am J Ind Med. 1984; 6(3): 173–183. DOI: 10.1002/ajim.4700060303
- Hinson AV, Schlünssen V, Agodokpessi G, et al. The prevalence of byssinosis among cotton workers in the north of Benin. Int J Occup Environ Med. 2014; 5: 194–200.
- Lacasse Y, Assayag E and Cormier Y. Myths and controversies in hypersensitivity pneumonitis. Semin Respir Crit Care Med. 2008; 29(6): 631–642. DOI: 10.1055/s-0028-1101273
- Spagnolo P, Rossi G, Cavazza A, et al. Hypersensitivity pneumonitis: A comprehensive review. J Investig Allergol Clin Immunol. 2015; 25(4): 237–250.
- Johannson KA, Balmes JR and Collard HR. Air pollution exposure: A novel environmental risk factor for interstitial lung disease? Chest. 2015; 147(4): 1161–1167. DOI: 10.1378/chest.14-1299
- Pinkerton KE.
A Critical Review of the Particulate Matter Toxicology Literature for Senate Bill 25 Review of the Particulate Matter Standard . Sacramento, CA: California Environmental Protection Agency, Air Resources Board, Research Division. 2002; 1–93. - Alexis NE, Lay JC, Hazucha M, et al. Low-level ozone exposure induces airways inflammation and modifies cell surface phenotypes in healthy humans. Inhal Toxicol. 2010; 22(7): 593–600. DOI: 10.3109/08958371003596587
- Scannell C, Chen L, Aris RM, et al. Greater ozone-induced inflammatory responses in subjects with asthma. Am J Respir Crit Care Med. 1996; 154(1): 24–29. DOI: 10.1164/ajrccm.154.1.8680687
- Song H, Tan W and Zhang X. Ozone induces inflammation in bronchial epithelial cells. J Asthma. 2011; 48(1): 79–83. DOI: 10.3109/02770903.2010.529224
- Larsen ST, Matsubara S, McConville G, et al. Ozone increases airway hyperreactivity and mucus hyperproduction in mice previously exposed to allergen. J Toxicol Environ Health A. 2010; 73(11): 738–747. DOI: 10.1080/15287391003614034
- Adamson IY and Hedgecock C. Patterns of particle deposition and retention after instillation to mouse lung during acute injury and fibrotic repair. Exp Lung Res. 1995; 21(5): 695–709. DOI: 10.3109/01902149509050837
- Beeh KM, Beier J, Haas IC, et al. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2002; 19(6): 1119–1123. DOI: 10.1183/09031936.02.00262402
- Grahame TJ and Schlesinger RB. Oxidative stress-induced telomeric erosion as a mechanism underlying airborne particulate matter-related cardiovascular disease. Part Fibre Toxicol. 2012; 9: 21. DOI: 10.1186/1743-8977-9-21
- Hou L, Wang S, Dou C, et al. Air pollution exposure and telomere length in highly exposed subjects in Beijing, China: A repeated-measure study. Environ Int. 2012; 48: 71–77. DOI: 10.1016/j.envint.2012.06.020
- Garcia CK. Idiopathic pulmonary fibrosis: Update on genetic discoveries. Proc Am Thorac Soc. 2011; 8(2): 158–162. DOI: 10.1513/pats.201008-056MS
- Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 2008; 105(35): 13051–13056. DOI: 10.1073/pnas.0804280105
- Adamson IY, Vincent R and Bjarnason SG. Cell injury and interstitial inflammation in rat lung after inhalation of ozone and urban particulates. Am J Respir Cell Mol Biol. 1999; 20(5): 1067–1072. DOI: 10.1165/ajrcmb.20.5.3468
- Adar SD, Huffnagle GB and Curtis JL. The respiratory microbiome: An underappreciated player in the human response to inhaled pollutants? Ann Epidemiol. 2016; 26(5): 355–359. DOI: 10.1016/j.annepidem.2016.03.010
- Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: An analysis of the COMET study. Lancet Respir Med. 2014; 2: 548–556. DOI: 10.1016/S2213-2600(14)70069-4
- Molyneaux PL and Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013; 22: 376–381. DOI: 10.1183/09059180.00000713
- Faner R, Sibila O, Agustí A, et al. The microbiome in respiratory medicine: Current challenges and future perspectives. Eur Respir J. 2017; 49(4): 1602086. DOI: 10.1183/13993003.02086-2016
- Devlin RB, Duncan KE, Jardim M, et al. Controlled exposure of healthy young volunteers to ozone causes cardiovascular effects. Circulation. 2012; 126(1): 104–111. DOI: 10.1161/CIRCULATIONAHA.112.094359
- Neophytou AM, Hart JE, Cavallari JM, et al. Traffic-related exposures and biomarkers of systemic inflammation, endothelial activation and oxidative stress: A panel study in the US trucking industry. Environ Health. 2013; 12: 105. DOI: 10.1186/1476-069X-12-105
- Patel MM, Chillrud SN, Deepti KC, et al. Traffic-related air pollutants and exhaled markers of airway inflammation and oxidative stress in New York City adolescents. Environ Res. 2013; 121: 71–78. DOI: 10.1016/j.envres.2012.10.012
- Last JA, Reiser KM, Tyler WS, et al. Long-term consequences of exposure to ozone. I. Lung collagen content. Toxicol Appl Pharmacol. 1984; 72(1): 111–118. DOI: 10.1016/0041-008X(84)90254-0
- Reiser KM, Tyler WS, Hennessy SM, et al. Long-term consequences of exposure to ozone. II. Structural alterations in lung collagen of monkeys. Toxicol Appl Pharmacol. 1987; 89(3): 314–322. DOI: 10.1016/0041-008X(87)90151-7
- Li YJ, Shimizu T, Hirata Y, et al. Diesel exhaust particle induce epithelial-to-mesenchymal transition by oxidative stress in human bronchial epithelial cell. Eur Respir J. 2013; 42(suppl 57):
P3896 . - Líbalová H, Uhlířová K, Kléma J, et al. Global gene expression changes in human embryonic lung fibroblasts induced by organic extracts from respirable air particles. Part Fibre Toxicol. 2012; 9: 1. DOI: 10.1186/1743-8977-9-1
- The World Health Organization. Ambient Air Pollution: A Global Assessment of Exposure and Burden of Disease; 2016.
http://www.who.int/phe/publications/air-pollution-global-assessment/en/ . Access date: September 15, 2016. - Fischer A and Chartrand S. Assessment and management of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2015; 32(1): 2–21.
- Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung diseases: A systematic review. Chest. 2014; 146(2): 422–436. DOI: 10.1378/chest.13-2626
- Kim EJ, Collard HR and King TE,
Jr . Rheumatoid arthritis-associated interstitial lung disease: The relevance of histopathologic and radiographic pattern. Chest. 2009; 136(5): 1397–1405. DOI: 10.1378/chest.09-0444 - Bryson T, Sundaram B, Khanna D, et al. Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: Similarity and difference. Semin Ultrasound CT MR. 2014; 35(1): 29–38. DOI: 10.1053/j.sult.2013.10.010
- Nana AM, Ngnie C, Wandji A, et al. Non-infectious lung manifestations of autoimmune diseases in Cameroon. Afr J Respir Med. 2012; 8(1): 12–14.
- Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010; 62(7): 2101–2108. DOI: 10.1002/art.27466
- Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354(25): 2655–2666. DOI: 10.1056/NEJMoa055120
- Shenoy PD, Bavaliya M, Sashidharan S, et al. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: A single-centre, retrospective analysis. Arthritis Res Ther. 2016; 18(1): 123. DOI: 10.1186/s13075-016-1015-0
- Strauss I, Liebermann KV and Churg J.
Pulmonary vasculitis . In: Fishman AP (ed.), Pulmonary Diseases and Disorders. 2nd ed. 1988; 1127–1156. New York: McGraw Hill Book Company. - Udwadia FE.
Pulmonary eosinophilic syndrome . In: Ahuja MMS (ed.), Progress in Clinical Medicine in India. 2nd series. 1978; 453–475. New Delhi: Arnold Heinemann. - Richeldi L, Rubin AS, Avdeev S, et al. Idiopathic pulmonary fibrosis in BRIC countries: The cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237. DOI: 10.1186/s12916-015-0495-0
- Avdeev SN. Idiopathic pulmonary fibrosis: Current concepts and diagnostic approaches. Practical Pulmonology. 2014; 4: 16–23.
- Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006; 61(11): 980–985. DOI: 10.1136/thx.2006.062836
- Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071–2082. DOI: 10.1056/NEJMoa1402584
- Wei LQ, Peng SC, Cao J, et al. Clinical features and diagnosis and treatment of diffuse interstitial lung disease: A multi-center study. Chinese General Practice. 2012; 15: 2521–2524.
- Exposito DB, Lanes S, Donneyong M, et al. Idiopathic pulmonary fibrosis in United States automated claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med. 2015; 192(10): 1200–1207. DOI: 10.1164/rccm.201504-0818OC
- Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. Eur Respir Rev. 2012; 21(126): 355–361. DOI: 10.1183/09059180.00002512
- Baddini-Martinez J and Pereira CA. How many patients with idiopathic pulmonary fibrosis are there in Brazil? J Bras Pneumol. 2015; 41(6): 560–561. DOI: 10.1590/s1806-37562015000000165
- Lederer DJ, Arcasoy SM, Barr RG, et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant. 2006; 6(10): 2436–2442. DOI: 10.1111/j.1600-6143.2006.01480.x
- Zeki AA, Schivo M, Chan AL, et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun. 2010; 34(3): J327–J338. DOI: 10.1016/j.jaut.2009.11.004
- Sgalla G, Biffi A and Richeldi L. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. Respirology. 2016; 21(3): 427–437. DOI: 10.1111/resp.12683
- Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review. Eur Respir J. 2015; 46(3): 795–806. DOI: 10.1183/09031936.00185114
- Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011; 66(6): 462–467. DOI: 10.1136/thx.2010.148031
- Maher TM, Strongman H, Boggon R, et al. Idiopathic pulmonary fibrosis survival has not improved in the 21st century: Analysis of CPRD gold primary care data. Thorax. 2013; 68(Suppl 3): A82–A83. DOI: 10.1136/thoraxjnl-2013-204457.168
- Kornum JB, Christensen S, Grijota M, et al. The incidence of interstitial lung disease 1995–2005: A Danish nationwide population-based study. BMC Pulm Med. 2008; 8: 24. DOI: 10.1186/1471-2466-8-24
- von Plessen C, Grinde O and Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med. 2003; 97(4): 428–435. DOI: 10.1053/rmed.2002.1466
- Rufino RL, Costa CH, Accar J, et al. Incidence and mortality of interstitial pulmonary fibrosis in Brazil. Am J Respir Crit Care Med. 2013; 187:
A1458 . - Fortuna FP, Perin C, Cunha L, et al. Mortality caused by idiopathic pulmonary fibrosis in the state of Rio Grande do Sul (Brazil). J Pneumologia. 2003; 29: 121–124. DOI: 10.1590/S0102-35862003000300002
- Lai CC, Wang CY, Lu HM, et al. Idiopathic pulmo nary fibrosis in Taiwan: A population-based study. Respir Med. 2012; 106(11): 1566–1574. DOI: 10.1016/j.rmed.2012.07.012
- Han S, Mok Y, Jee SH and Danoff SK. Incidence and mortality of idiopathic pulmonary fibrosis in South Korea. Am J Respir Crit Care Med. ATS. 2013; A1460.
https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A1460 . - Munakata M, Asakawa M, Hamma Y, et al. Present status of idiopathic interstitial pneumonia-from epidemiology to etiology. Nihon Kyobu Shikkan Gakkai Zasshi. 1994; 32: 187–192.
- Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014; 190(7): 773–779. DOI: 10.1164/rccm.201403-0566OC
- Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc. 2014; 11(8): 1176–1185. DOI: 10.1513/AnnalsATS.201404-145OC
- Raghu G, Chen SY, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016; 48(1): 179–186. DOI: 10.1183/13993003.01653-2015
- Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014; 108(5): 793–799. DOI: 10.1016/j.rmed.2013.09.002
- Agabiti N, Porretta MA, Bauleo L, et al. Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(3): 191–197.
- Jo H, Glaspole I, Moodley Y, et al. Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry. Eur Resp J. 2016; 48(Suppl 60). DOI: 10.1183/13993003.congress-2016.PA2100
- Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg. 2005; 49(3): 259–265.
- Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case-control study. Collaborating Centers. Am J Epidemiol. 2000; 152(4): 307–315. DOI: 10.1093/aje/152.4.307
- Britton J and Hubbard R. Recent advances in the aetiology of cryptogenic fibrosing alveolitis. Histopathology. 2000; 37(5): 387–392. DOI: 10.1046/j.1365-2559.2000.01098.x
- Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788–824. DOI: 10.1164/rccm.2009-040GL
- Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: A risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997; 155(1): 242–248. DOI: 10.1164/ajrccm.155.1.9001319
- Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: Outcome in relation to smoking status. Am J Respir Crit Care Med. 2008; 177(2): 190–194. DOI: 10.1164/rccm.200612-1759OC
- Richards TJ, Kuhlengel TK, Choi J, et al. Does ambient air pollution exposure modify longitudinal disease outcome in a cohort of patients with idiopathic pulmonary fibrosis? Am J Respir Crit Care Med. ATS. 2011;
A5433 . DOI: 10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A5433 - Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014; 43(4): 1124–1131. DOI: 10.1183/09031936.00122213
- Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994; 150(3): 670–675. DOI: 10.1164/ajrccm.150.3.8087336
- Mejia M, Carillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009; 136(1): 10–15. DOI: 10.1378/chest.08-2306
- Mathai SK, Yang IV, Schwarz MI, et al. Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis. BMC Med. 2015; 13(1): 191. DOI: 10.1186/s12916-015-0434-0
- Whitsett JA, Wert SE, Weaver TE. Diseases of pulmonary surfactant homeostasis. Annu Rev Pathol. 2015; 10: 371–93. DOI: 10.1146/annurev-pathol-012513-104644
- Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016; 48(6): 1710–1720. DOI: 10.1183/13993003.00308-2016
- Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364(16): 1503–12. DOI: 10.1056/NEJMoa1013660
- Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013; 45(6): 613–20. DOI: 10.1038/ng.2609
- Meyer KC. Pulmonary fibrosis, part I: Epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med; 2017. DOI: 10.1080/17476348.2017.1312346
- King CS and Nathan SD. Idiopathic pulmonary fibrosis: Effects and optimal management of comorbidities. Lancet Respir Med. 2017; 5(1): 72–84. DOI: 10.1016/S2213-2600(16)30222-3
- Sundaram B, Gross BH, Martinez FJ, et al. Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: Effect of predominance and distribution of findings. Am J Roentgenol. 2008; 191: 1032–1039. DOI: 10.2214/AJR.07.3177
- Brownell R, Moua T, Henry TS, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017; 72(5): 424–429. DOI: 10.1136/thoraxjnl-2016-209671
- Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015; 192: e3–19. DOI: 10.1164/rccm.201506-1063ST
- Schünemann HJ, Oxman AD, Brozek J, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. Br Med J. 2008; 17: 1106–10. DOI: 10.1136/bmj.39500.677199.AE
- Xaubet A, Molina-Molina M, Acosta O, et al. Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol. 2017; 53(5): 263–269. DOI: 10.1016/j.arbres.2016.12.011
DOI: https://doi.org/10.5334/aogh.2414 | Journal eISSN: 2214-9996
Language: English
Published on: Jan 22, 2019
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2019 Pilar Rivera-Ortega, Maria Molina-Molina, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.